Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Britain Courts Anthropic Amid US Defense Department Dispute 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
- Application filed with IP Australia would expand patent estate to immunotherapy
- Creates new opportunities in the growing field of immunotherapy and reinforces a position in oncology
MELBOURNE, Australia, June 20, 2017 -- Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), announced today that the Company has filed a new patent application with IP Australia for oncology-related therapeutic uses of its proprietary Cymerus™ mesenchymal stem cell (MSC) technology.
The patent would cover the application of Cymerus in immunotherapy treatments, including chimeric antigen receptor T cell (CAR-T) and checkpoint inhibitor-based therapies. Cynata recently announced the filing of another patent application with IP Australia covering uses of Cymerus in oncology.
“We are thrilled to announce the filing of this patent application, which would strengthen our intellectual property portfolio in the oncology field and expand commercial opportunities for Cymerus in immunotherapy,” said Dr Ross Macdonald, Cynata’s Managing Director and Chief Executive Officer. “Immunotherapy is one of the most exciting areas in oncology and our new intellectual property ensures Cynata is well-positioned to capitalise on future growth in the field.”
About Cynata Therapeutics (ASX:CYP)
Cynata Therapeutics Limited (ASX:CYP) is an Australian clinical-stage stem cell and regenerative medicine company developing therapies based on its proprietary Cymerus™ stem cell technology platform. Cymerus overcomes critical issues in the production of therapeutic mesenchymal stem cells (MSCs) by enabling the economical manufacture of commercial-scale MSCs, independent of multi-donor limitations. Cymerus’ novel approach utilises induced pluripotent stem cells (iPSCs) derived from a single blood donation to generate mesenchymoangioblasts (MCAs), a precursor that is used to manufacture an unlimited number of therapeutic MSCs. Cynata’s unique “off-the-shelf” Cymerus platform has the potential to create a new standard in the development and manufacture of stem cell therapeutics.
CONTACTS: Dr Ross Macdonald, CEO, 0412 119343, [email protected] Andrew Ramadge, Australia Media Contact, 0475 797 471, [email protected] Laura Bagby, U.S. Media Contact, 312-448-8098, [email protected]
